Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
复制标题
DOI：
10.1002/hep.30297
复制
发表时间：
2019-03
期刊：
影响因子：
--
通讯作者：
Ryerson AB
中科院分区：
文献类型：
--
作者：
Hofmeister MG;Rosenthal EM;Barker LK;Rosenberg ES;Barranco MA;Hall EW;Edlin BR;Mermin J;Ward JW;Ryerson AB
丙型肝炎病毒（HCV）感染是美国最常见的血液传播感染，导致大量的发病率和死亡率，每年花费数十亿美元。为了更新美国所有年龄≥18岁成年人的估计HCV患病率，我们分析了2013-2016年国家健康和营养检查调查（NHANES）的数据，以估计非机构化平民人群的HCV患病率，并使用文献综述和人口规模估计方法相结合，估计HCV的患病率和人口规模为4个额外的人口：被监禁的人，无家可归的人，现役军人和养老院居民。我们估计，在2013-2016年期间，（95% CI 1.4-2.0%），在美国所有成人中，约4.1（340 - 490）万人为HCV抗体阳性所有成人中有1.0%（95% CI 0.8-1.1%），约240万（200 - 280万）人为HCV RNA阳性（表明当前感染）。这包括美国370万非住院平民成人与HCV抗体和210万与HCV RNA，估计有38万HCV抗体阳性的人和25万HCV RNA阳性的人不属于2013-2016 NHANES抽样框架。2013-2016年期间，美国有超过200万人目前感染HCV。与过去基于类似方法的估计相比，HCV抗体流行率可能增加，而RNA流行率可能下降，可能反映了阿片类药物危机，HCV感染的治愈性治疗和HCV感染人群的死亡率的组合。需要在多个方面做出努力，以应对不断演变的HCV流行病，包括增加HCV检测的能力和可及性，与护理的联系和治愈。
Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually. To update the estimated HCV prevalence among all adults aged ≥18 years in the United States, we analyzed 2013-2016 data from the National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of HCV in the noninstitutionalized civilian population, and used a combination of literature reviews and population size estimation approaches to estimate the HCV prevalence and population sizes for four additional populations: incarcerated people, unsheltered homeless people, active-duty military personnel, and nursing home residents. We estimated that during 2013-2016, 1.7% (95% CI 1.4-2.0%) of all adults in the United States, approximately 4.1 (3.4-4.9) million persons, were HCV antibody-positive (indicating past or current infection), and 1.0% (95% CI 0.8-1.1%) of all adults, approximately 2.4 (2.0-2.8) million persons, were HCV RNA-positive (indicating current infection). This includes 3.7 million noninstitutionalized civilian adults in the United States with HCV antibodies and 2.1 million with HCV RNA, and an estimated 0.38 million HCV antibody-positive persons and 0.25 million HCV RNA-positive persons not part of the 2013-2016 NHANES sampling frame. Over 2 million people in the United States had current HCV infection during 2013-2016. Compared to past estimates based on similar methodology, HCV antibody prevalence may have increased while RNA prevalence may have decreased, likely reflecting the combination of the opioid crisis, curative treatment for HCV infection, and mortality among the HCV-infected population. Efforts on multiple fronts are needed to combat the evolving HCV epidemic, including increasing capacity for and access to HCV testing, linkage-to-care, and cure.
登录
查看更多内容
影响因子：
39.2
作者：
Denniston MM;Jiles RB;Drobeniuc J;Klevens RM;Ward JW;McQuillan GM;Holmberg SD
通讯作者：
Holmberg SD
DOI：
10.1007/s11524-015-9945-4
发表时间：
2015-04-01
影响因子：
6.6
作者：
Kuncio, Danica E.;Newbern, E. Claire;Viner, Kendra M.
通讯作者：
Viner, Kendra M.
影响因子：
13.5
作者：
Belperio, Pamela S.;Shahoumian, Troy A.;Backus, Lisa I.
通讯作者：
Backus, Lisa I.
影响因子：
3.3
作者：
Cocoros, Noelle;Nettle, Eduardo;DeMaria, Alfred, Jr.
通讯作者：
DeMaria, Alfred, Jr.
影响因子：
158.5
作者：
Afdhal, Nezam;Zeuzem, Stefan;Marcellin, Patrick
通讯作者：
Marcellin, Patrick